by CCHR National Affairs Office | Jan 25, 2024
Recent research and antidepressant users’ lived experience show that antidepressant withdrawal symptoms may be severe and long-lasting. Patients and their prescribers need accurate information on withdrawal risks and tapering guidance from the FDA. A mounting body of...
by CCHR National Affairs Office | Jan 18, 2024
Citizens Commission on Human Rights says American Psychiatric Association’s unwillingness to provide full disclosure of pharmaceutical companies’ payments to psychiatrists involved in developing the latest edition of the Diagnostic and Statistical Manual of Mental...
by CCHR National Affairs Office | Jan 10, 2024
Mental health watchdog CCHR presses for DEA reclassification of benzodiazepines due to risks of physical dependency and addiction. The use of benzodiazepines during pregnancy increases the risk of miscarriage, new research has indicated. A separate study...
by CCHR National Affairs Office | Jan 4, 2024
Teens guessing they were taking an antidepressant led to substantial improvement, while actual treatment with the drug did not, researchers found. Prescribing an antidepressant to depressed teens is challenged by a new study finding that the drug’s apparent...
by CCHR National Affairs Office | Dec 28, 2023
Young, male, Black, and economically disadvantaged children were disproportionately restrained with antipsychotic drugs. The use of antipsychotic drugs to chemically restrain agitated children who are hospitalized for mental health conditions rose 141% in recent...
